JPRN-jRCTs041230120招募中3 期
A pragmatic, randomized phase III trial of bi-weekly versus conventional schedule of TAS-102 plus bevacizumab for metastatic colorectal cancer (PRABITAS)
Taniguchi Hiroya0 个研究点目标入组 890 人开始时间: 2023年12月21日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 890
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1) Histopathologically diagnosed as adenocarcinoma of the colon.
- •2) Diagnosed as metastatic colorectal cancer.
- •3) Age 18 years or older on the date of consent.
- •4) ECOG PS of 0-2.
- •5) Confirmed RAS gene status by tumor tissue.
- •6) Received all fluoropyrimidines, oxaliplatin, irinotecan and molecular targeted agents.
- •7) No previous administration of FTD/TPI.
- •8) Ability to safely receive the protocol treatment.
- •9) Written informed consent obtained from the patient.
排除标准
- •1) History of severe hypersensitivity reactions to components of FTD/TPI or BEV.
- •2) Pregnant or potentially pregnant women.
- •3) History of hemoptysis (more than 2.5 ml of fresh blood)
- •4)Judged ineligible for trial participation by the investigator.
研究者
相似试验
招募中
不适用
Randomized Phase III Clinical Trial of Weekly versus Tri-weekly Cisplatin Based Chemoradiation in Locally Advanced Cervical CancerNeoplasmsKCT0003214Korea Cancer Center Hospital374
进行中（未招募）
不适用
A randomized phase III studyComparing biweekly and tailored epirubicin + cyclophosphamide followed by biweekly tailored docetaxel (dtEC -- dtT)(A-arm) versus three weekly epirubicin + cyclophosphamide, 5-fluorouracil followed by docetaxel (FEC -- T)(B-arm) in lymph node positive or high risk lymph node negative breast cancer patients- a continuation of the feasibility part of the SBG 2004-1 study - PANTHERymph node positive or high risk lymph node negative breast cancer patients.MedDRA version: 16.1Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2007-002061-12-DESBG2,000
已完成
2 期
A Randomized Phase II/III Trial of Tri-weekly Intravenous versus Tri-weekly Intraperitoneal Carboplatin Both in Combination with Weekly Intravenous Paclitaxel for Newly Diagnosed Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal CancerEpithelial Ovarian, Fallopian Tube, and Primary Peritoneal CancerJPRN-UMIN000003670Gynecologic Oncology Trial and Investigation Consortium / Japanese Gynecologic Oncology Group655
进行中（未招募）
1 期
A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube CancerRecurrent partially platinum sensitive or resistant epithelial ovarian, primary peritoneal or fallopian tube cancersMedDRA version: 17.0Level: PTClassification code 10066697Term: Ovarian cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-019821-32-CZAmgen Inc.919
未知
3 期
AMG 386 2nd Ovarian cancer Global Phase 3 clinical trialRecurrent partially platinum sensitive or resistant epithelial ovarian, primary peritoneal or fallopian tube cancersJPRN-jRCT2080221277Takeda Pharmaceutical Company Limited900